Medicare's outpatient payment rule addresses device recalls
This article was originally published in Clinica
US Medicare is proposing to reduce what it pays hospitals for implanting defibrillators and other devices when the procedure is being done to replace a product that is still under warranty or is subject to a manufacturer's product recall.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.